Published in

Elsevier, Transplantation Proceedings, 2(41), p. 537-538

DOI: 10.1016/j.transproceed.2009.01.011

Links

Tools

Export citation

Search in Google Scholar

Dendritic Cell Therapy in Composite Tissue Allotransplantation

Journal article published in 2009 by A. W. Thomson, J. M. Sacks, Y.-R. Kuo, R. Ikeguchi, E. K. Horibe, J. Unadkat ORCID, M. G. Solari, M. Feili-Hariri, W. P. A. Lee
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Dendritic cells (DCs) are bone marrow-derived, professional antigen-presenting cells, with inherent tolerogenic function. The ability of immature or maturation-resistant DCs to regulate alloantigen-specific T-cell responses and to promote tolerance induction has been well demonstrated in organ and bone marrow transplantation. Recent data suggest that DCs can also promote long-term survival of composite tissue allografts in the absence of continued immunosuppressive drug therapy.